Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 88.6 0.70% 0.62
NBIX closed up 0.7 percent on Thursday, January 17, 2019, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical NBIX trend table...

Date Alert Name Type % Chg
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 17 Up 3 Days in a Row Strength 0.00%
Jan 16 Shooting Star Candlestick Bearish 0.70%
Jan 16 Doji - Bearish? Reversal 0.70%
Jan 16 Multiple of Ten Bearish Other 0.70%
Jan 16 Wide Bands Range Expansion 0.70%

Older signals for NBIX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Is NBIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 Neurocrine's Ingrezza shows positive effect in patients with mood disorders
Jan 16 New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
Jan 16 4 Defensive Stocks to Buy Amid Shutdown and Brexit
Jan 15 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results
Jan 15 Here’s your guide to the upcoming biotechnology takeover wave
Jan 14 Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences
Jan 11 Biotech Stocks Are Enjoying Their Best-Ever Start to the Year
Jan 11 Is Neurocrine Biosciences, Inc.’s (NASDAQ:NBIX) CEO Overpaid Relative To Its Peers?
Jan 10 5 Biotech Stocks That Could Face M&A Next!
Jan 9 Neurocrine Biosciences (NBIX) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
See more NBIX news...
Indicators
Indicator Value
52 Week High 126.98
52 Week Low 64.72
Average Volume 1,316,573
200-Day Moving Average 98.716
50-Day Moving Average 84.7388
20-Day Moving Average 77.4355
10-Day Moving Average 84.69
Average True Range 3.8976
ADX 35.09
+DI 28.7898
-DI 18.7758
Chandelier Exit (Long, 3 ATRs ) 78.4172
Chandelier Exit (Short, 3 ATRs ) 78.40279999999999
Upper Bollinger Band 93.018
Lower Bollinger Band 61.853
Percent B (%b) 0.86
BandWidth 40.246399
MACD Line 1.587
MACD Signal Line -0.6919
MACD Histogram 2.2789
Fundamentals Value
Market Cap 7.81 Billion
Num Shares 88.2 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -35.16
Price-to-Sales 826.51
Price-to-Book 15.16
PEG Ratio 1.78
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 91.37
Resistance 3 (R3) 91.42 90.55 90.91
Resistance 2 (R2) 90.55 89.85 90.53 90.75
Resistance 1 (R1) 89.58 89.41 90.07 89.52 90.60
Pivot Point 88.71 88.71 88.95 88.68 88.71
Support 1 (S1) 87.73 88.00 88.22 87.68 86.60
Support 2 (S2) 86.86 87.57 86.84 86.45
Support 3 (S3) 85.89 86.86 86.29
Support 4 (S4) 85.83